Despite recent therapeutic advances, pulmonary hypertension (PH) remains a fatal disease
due to the development of right ventricular (RV) failure. At present, no treatments targeted at …

We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various
animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis …

Background Malignant ventricular arrhythmia (VA) is a major contributor to sudden cardiac
death (SCD) in patients with pulmonary arterial hypertension (PAH)-induced right heart …

Objectives: We sought to study whether patients with right ventricular failure (RVF)
secondary to chronic thromboembolic pulmonary hypertension (CTEPH) have reduced left …

Pulmonary hypertension (PH) is characterized by elevated pulmonary arterial pressure,
which leads to right ventricular (RV) hypertrophy and failure. The pathophysiological …

Most patients with pulmonary arterial hypertension die from right ventricular failure (RVF).
Right ventricular (RV) myocardial apoptosis has an important role in RVF and is regulated …

Recent studies have demonstrated that the expression of sphingosine kinase 1, the enzyme
that catalyses formation of the bioactive lipid, sphingosine 1-phosphate, is increased in …

Background—Right ventricular failure (RVF) in pulmonary hypertension (PH) is associated
with increased incidence of sudden death by a poorly explored mechanism. We test the …

Aims Inflammatory activation plays an important role in the pathogenesis and progression of
left ventricular (LV) heart failure. In right ventricular (RV) heart failure, little is known about …

Sphingosine kinase 1 (SphK1) knockout mice are protected against pulmonary hypertension
and expression levels of the enzyme are increased in the lungs of pulmonary arterial …